Dear Editor,
Sulfate is an obligate nutrient for numerous cellular and metabolic processes important for fetal development [1] . Fetal tissues express sulfotransferases which conjugate sulfate (sulfonate) to molecules such as steroids and hormones, leading to their inactivation [2] . In addition, sulfonation of glycosaminoglycans is important for development of some tissues, as several growth factor gradients and ligand-receptor interactions are dependent on these sulfonated extracellular constituents [3] . Not surprisingly therefore, reduced sulfonation capacity has been linked to disorders of skeletal, eye, vascular and craniofacial development, demonstrating a critical requirement for sulfate in these tissues [4] . Despite a fundamental role for sulfate during development, the fetus appears to have a limited capacity to generate sulfate from sulfur-containing amino acids, and is thought to be reliant on maternal sulfate provision [5] . In fact, maternal serum sulfate levels increase two-fold during pregnancy, and provide a potential reservoir for fetal consumption [6, 7] . The elevated sulfate levels are due to increased sulfate reabsorption in the maternal kidneys, mediated by increased expression of the SLC13A1 sulfate transporter [7] . The importance of maintaining high maternal sulfate levels in pregnancy is highlighted by the hyposulfatemia seen in pregnant Slc13a1 −/− mice, which causes fetal hyposulfatemia and late gestational fetal loss.
Despite its importance in fetal development, relatively little is known about how sulfate traverses the placenta. The sulfate transporter SLC13A4 is expressed predominantly in the placenta, where it is proposed to mediate sulfate supply to the fetus [8] . Previously we examined the spatial localization of all 10 sulfate transporters in human [9] and mouse placenta [8] and identified Slc13a4 as the most abundant sulfate transporter localized to the transporting syncytiotrophoblasts. In the current study we describe the critical requirement of placental Slc13a4 activity for normal fetal development in mice.
We generated Slc13a4 knockout mice using ES cells sourced from the European Conditional Mouse Mutant Figure  S2A ), which became more severe at E14.5 (Supplementary information, Figure S2A ) and E16.5 (Figures 1C and Supplementary information, Figure S2A ), with fetal death occurring by E18.5. The most striking phenotypes at E16.5 were pale skin, subcutaneous oedema, craniofacial malformations, vascular hemorrhaging and skeletal defects ( Figure 1C ). We measured unidirectional maternal-fetal transfer of 35 S-sulfate as fetal accumulation of radioisotope at E12.5 after injection into the maternal circulation. At E12.5 35 S-sulfate per gram of placenta was significantly lower in Slc13a4 KOF/KOF embryos compared with Slc13a4 +/KOF and Slc13a4 +/+ littermate controls (P < 0.001; Figure 1B , Supplementary information, Figure  S3A ). Additionally we measured elemental sulfur levels (Supplementary information, Figure S3C) KOF/KOF embryos. Mutations in genes required for intracellular sulfonation have been extensively studied and linked to developmental phenotypes in mice and humans [10] . For example, the sulfonation of ECM components such as heparin sulfate proteoglycans is critical for growth factor binding and signalling. Mutations within specific heparin sulfotransferases cause defects in eye morphogenesis [11] , skeletal and craniofacial development [11] or affect vascular patterning in vivo [12] , depending on the organ or tissue the sulfotransferase is endogenously expressed. By contrast, the phenotypes present in Slc13a4 KOF/KOF embryos affect multiple tissues, including the skeleton ( Figure  1D ), vasculature ( Figure 1E ), eye (iris coloboma and increased lens thickness) ( Figure 1F ) and palate ( Figure  1G ), all of which have been individually linked to sulfotransferases or sulfate transporter genes (Supplementary information, Table S1 ). As the phenotype of Slc13a4 KOF/ KOF embryos encompasses those of multiple sulfotransferase mutants, it is therefore likely the reflection of a global reduction in sulfate supply to the embryo via the placenta. Importantly, while the skeletons of Slc13a4 KOF/ KOF embryos displayed a total lack of calcification (alizarin red staining), Slc13a4 +/KOF skeletons had an intermediate phenotype with reduced calcification compared with wildtype controls ( Figure 1D , middle panel), suggesting that haploinsufficiency of Slc13a4 is also sufficient to perturb or delay fetal skeletal maturation.
While the placenta expresses a multitude of transporters and channels to facilitate the supply of nutrients such as ions, amino acids, fatty acids, minerals, and glucose to the fetus, studies of gene knockout mice often overlook the contribution of placental supply when investigating the role of individual transporters in fetal development and adult disease. Importantly, the development of placentas from Slc13a4 null embryos appeared normal throughout gestation (Supplementary information, Figure S4) . This is an important observation as defects in placental development are known to cause fetal growth restriction [13] ; we do not see a generalized growth restriction in Slc13a4 KOF/KOF or Slc13a4 −/− embryos. Normal development of Slc13a4 KOF/KOF placentas therefore suggests that the tissue-specific embryonic phenotypes are the result of reduced placental SLC13A4 transport activity rather than generalized placental insufficiency and growth restriction as a result of aberrant placental development.
To confirm that the developmental phenotypes and late gestational lethality observed in Slc13a4 null embryos are due to loss of placental Slc13a4 activity, and not due to embryonal tissue-specific requirements for Slc13a4, we generated an Slc13a4 conditional knockout allele by mating Slc13a4 +/KOF mice with FLPeR-expressing mice to produce a conditional Slc13a4 "floxed" allele (Slc13a4 Figure 1H , Supplementary information, Figure S1A ). The conditional allele, when deleted globally through the maternal inheritance of the Sox2-Cre transgene (Tg) [14] , produced the same phenotypes as seen with the Slc13a4 KOF/KOF . Furthermore, crosses of resultant Table S2 and Figure S1 ). Figure 1I , J, Supplementary information, Figure S5 and S6) Sox2-driven Cre recombinase expression/activity is restricted to the embryonic epiblast, but is absent from extra-embryonic tissues such as the syncytiotrophoblast where Slc13a4 is endogenously expressed. Litters from Slc13a4
Flx/Flx crosses were analyzed on the day of birth (P0.5) and all the resultant pups were genotyped at postnatal day (P)8. Slc13a4
−/−

Tg
Sox2Cre pups were present within each litter examined from these crosses (Supplementary information, Figure 1K , Supplementary information, Figure S3B ). Slc13a4 −/− Tg Sox2Cre mice from these crosses were indistinguishable from heterozygous littermate controls and analysis of Slc13a4
−/−
Tg
Sox2Cre embryos at E16.5 demonstrated the rescue of all previously observed phenotypes when Slc13a4 expression was maintained in the placenta ( Figure 1L, M) . Importantly Slc13a4 −/− Tg Sox2Cre mice survive through to adulthood ( Figure 1N ). The rescue of severe and lethal embryonic defects in Slc13a4 −/− Tg Sox2Cre embryos when Slc13a4 expression is retained in the placenta, but not the embryo itself, demonstrates the dependence of the fetus on access to circulating maternal sulfate stores via the placenta for normal development. These findings also confirm that the fetus cannot produce enough sulfate from the metabolism of sulfur-containing amino acids to sustain development. To date the role of placental sulfate supply in the development of fetal tissues with a high demand for sulfate metabolism and sulfonation reactions has not been widely considered. The current study highlights a placental contribution to sulfate-dependent fetal abnormalities, and warrants further investigation of placental sulfate transport in human gestation.
